Recombinant obligate anaerobic gram-positive bacteria
US10266601B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 24, 2014 |
| Grant date | Apr 23, 2019 |
| Priority date | — |
| Expiry date | Aug 9, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.